< Back to previous page
Researcher
Michel Delforge
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Hematology (Division)
Member
From1 Jan 2021 → Today - Stem Cell and Developmental Biology (Division)
Member
From1 Apr 2013 → 31 Dec 2020 - Faculty of Medicine (Faculty)
Member
From1 Oct 2000 → 30 Sep 2002
Projects
1 - 10 of 19
- Ultra-sensitive minimal residual disease assessment by blood-based clonotypic mass spectrometry approach in plasma cell dyscrasias (MASSIAS)From1 Jan 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Optimizing the use of bispecific antibody treatment in Multiple Myeloma by studying the immune microenvironment and cellular mechanisms of drug resistance.From1 Oct 2023 → TodayFunding: FWO Strategic Basic Research Grant
- Ultra-sensitive minimal residual disease assessment by blood-based clonotypic mass spectrometry approach in plasma cell dyscrasias (MASSIAS)From1 Oct 2023 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Development, Validation, and Valorization of a Patient Preference Platform to Inform Healthcare Decision-MakingFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Positron emission tomography combined with innovative laboratory techniques for improved risk and disease assessment in myeloma.From1 Jan 2021 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Risk prediction and modeling of cancer therapy related cardiotoxicityFrom1 Oct 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Atomic Force Microscopy Enhanced Spectroscopy to Study Strains and Seeding of Amyloids In SituFrom1 May 2020 → TodayFunding: FWO Medium Size Research Infrastructure
- Augmenting THherapeutic Effectiveness through Novel AnalyticsFrom1 Apr 2020 → 31 Dec 2023Funding: VLAIO - Personalised Medicine ICON
- Het KU Leuven Kankerinstituut (LKI): interdisciplinaire samenwerking ter bevordering van kankeronderzoek, kankerbehandeling en –zorg.From1 Jan 2020 → TodayFunding: BOF - research organisations
- Unravelling the mechanisms of drug resistance to proteasome inhibitors to optimize treatment in patients with multiple myeloma.From1 Jul 2019 → 30 Jun 2023Funding: Foundations, funds and other with scientific goal
Publications
221 - 230 of 265
- Role of palifermin for autologous hematopoietic stem cell transplantation after conditioning with high-dose melphalan(2010)
Authors: Kristof Verraes, Michel Delforge
Pages: 457 - 457 - Current insight into thrombotic thrombocytopenic purpura(2010)
Authors: Len Verbeke, Michel Delforge, Daan Dierickx
Pages: 3 - 10 - The treatment of hematologic malignancies in pregnancy(2010)
Authors: Christophe Vandenbriele, Daan Dierickx, Frédéric Amant, Michel Delforge
Pages: 74 - 87 - VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study(2009)
Authors: Michel Delforge
Pages: 6086 - 6093 - Use of interval-specific likelihood ratios improves clinical interpretation of serum FLC results for the diagnosis of malignant plasma cell disorders(2009)
Authors: Pieter Vermeersch, Michel Delforge, Xavier Bossuyt
Pages: 54 - 58 - Use of interval-specific likelihood ratios improves clinical interpretation of serum FLC results for the diagnosis of malignant plasma cell disorders(2009)
Authors: Pieter Vermeersch, Martine Vercammen, Annelies Holvoet, Isabelle Vande Broeck, Michel Delforge, Xavier Bossuyt
Pages: 54 - 58 - Monocytes from patients with myelodysplastic syndromes are more resistant to inhibition by thalidomide(2009)
Authors: Gregor Verhoef, Michel Delforge
Pages: 769 - 770 - Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival(2009)
Authors: Michel Delforge
Pages: 627 - 636 - Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a belgian retrospective multicentric study(2009)
Authors: D Dierickx, Gregor Verhoef, A Van Hoof, P Mineur, A Roest, A Triffet, A Kentos, P Pierre, D Boulet, G Bries, et al.
Pages: 434 - 434 - The t(14;20)(q32;q12): A Rare Cytogenetic Change in Multiple Myeloma (MM) Associated with Poor Outcome(2009)
Authors: Lucienne Michaux, Michel Delforge, Peter Vandenberghe
Pages: 901 - 904
Patents
1 - 2 of 2
- Cell therapy for myelodysplastic syndromes (Inventor)
- CELL THERAPY FOR MYELODYSPLASTIC SYNDROMES (Inventor)